GSA Capital Partners LLP Sells 148,530 Shares of Altimmune, Inc. (NASDAQ:ALT)

GSA Capital Partners LLP lessened its stake in shares of Altimmune, Inc. (NASDAQ:ALT) by 30.4% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 339,595 shares of the company’s stock after selling 148,530 shares during the period. GSA Capital Partners LLP’s holdings in Altimmune were worth $2,085,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of ALT. Hennion & Walsh Asset Management Inc. grew its position in shares of Altimmune by 34.7% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 174,108 shares of the company’s stock valued at $1,069,000 after acquiring an additional 44,832 shares during the period. Creative Planning raised its stake in Altimmune by 20.5% in the third quarter. Creative Planning now owns 18,411 shares of the company’s stock valued at $113,000 after buying an additional 3,132 shares during the period. Exchange Traded Concepts LLC lifted its position in shares of Altimmune by 74.4% in the third quarter. Exchange Traded Concepts LLC now owns 216,761 shares of the company’s stock valued at $1,331,000 after buying an additional 92,498 shares during the last quarter. PVG Asset Management Corp bought a new position in shares of Altimmune during the 2nd quarter worth approximately $154,000. Finally, B. Riley Wealth Advisors Inc. acquired a new position in shares of Altimmune during the 2nd quarter worth approximately $138,000. 78.05% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director David Drutz sold 16,011 shares of the business’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $6.90, for a total value of $110,475.90. Following the completion of the transaction, the director now owns 41,958 shares of the company’s stock, valued at $289,510.20. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 4.10% of the company’s stock.

Analyst Ratings Changes

ALT has been the subject of a number of research analyst reports. Evercore ISI raised shares of Altimmune to a “strong-buy” rating in a research report on Friday, August 9th. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research note on Thursday, August 22nd. B. Riley restated a “buy” rating and set a $20.00 price objective on shares of Altimmune in a report on Monday, August 12th. Finally, UBS Group initiated coverage on Altimmune in a research note on Tuesday. They set a “buy” rating and a $26.00 target price on the stock. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Altimmune Trading Up 29.1 %

Shares of ALT stock opened at $9.49 on Wednesday. The stock has a market cap of $674.45 million, a P/E ratio of -5.86 and a beta of 0.09. Altimmune, Inc. has a 1 year low of $2.32 and a 1 year high of $14.84. The stock has a 50 day simple moving average of $6.89 and a 200 day simple moving average of $6.87.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.